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This editorial refers to ‘Cocoa procyanidins inhibit
expression and activation of MMP-2 in vascular smooth
muscle cells by direct inhibition of MEK and MT1-MMP
activities’ by K.W. Lee et al., pp. 34–41,5 this issue.
Numerous epidemiological studies have indicated a role of
different nutrients and phytochemicals in reducing the risk
of cardiovascular disease, although the mechanisms are far
from clear. Cocoa is one of the most concentrated sources
of flavonols, a subgroup of the natural antioxidant com-
pounds called flavonoids, also found in tea and red wine.
Flavonoids, in turn, are a subgroup of compounds called
polyphenols. Animal as well as human studies have shown
beneficial changes in biological phenomena related to cardi-
ovascular health after the consumption of polyphenol-rich
foods such as cocoa, red wine, tea, and berries.1–3 Evidence
that flavonol-rich cocoa contributes to health is convincing
among Kuna Indians living off the coast of Panama, who
have no increase in blood pressure with age and very low
incidence of hypertension. The major chemical cocoa
mediators have been identified, including the monomers
epicatechin and catechin, and possibly procyanidins and
metabolites.4 In a carefully controlled series of in vitro
experiments, Lee et al.5 present an article in this issue of
Cardiovascular Research describing new protective effects
of cocoa on cardiovascular disease and atherosclerosis,
adding to the list of cocoa-related cardiovascular protective
mechanisms.
Polyphenols affect pathways related to cardiovascular
health by several different antioxidation-dependent and
-independent mechanisms. For instance, beneficial effects
have been observed in humans after ingestion of cocoa on
blood pressure, HDL-cholesterol, platelet aggregation, and
endothelial function.6–8 The beneficial effects of cocoa on
vascular function may be mediated through an antioxidant
action, mainly related to improved nitric oxide bioavailabil-
ity via either enhanced nitric oxide production or decreased
nitric oxide inactivation.9 Furthermore, cocoa is able
to increase the vasodilatory prostacyclin and to decrease
leukotrienes through the modulation of the endothelial
cell eicosanoid system pathway by inhibiting 5-lipoxygenase.
The reduction in the plasma leukotriene/prostacyclin
ratio, a measure of the proinflammatory/anti-inflammatory
eicosanoid balance, indicates that cocoa may have an
anti-inflammatory effect. Because inflammation is associ-
ated with increased aortic stiffness, this anti-inflammatory
effect of cocoa may also play a role in its beneficial effect
on arterial function.10
It is now widely accepted that atherosclerosis is an
inflammatory disease of the arterial vascular wall. Inflam-
mation is a complex process that involves distinct cellular
players and requires the occurrence of several steps includ-
ing cell migration as well as synthesis of extracellular
matrix (ECM) leading to the atherosclerotic fibrous
plaque; in later stages, ECM degradation results in plaque
disruption responsible for the clinical atherothrombotic
syndromes. ECM degradation is tightly regulated within
the normal vessel wall through a balance between protein-
ases and their endogenous inhibitors. However, within the
atherosclerotic plaque, the balance may become shifted
towards matrix degradation, particularly at the rupture-
prone shoulder regions of the fibrous cap where accumulat-
ing macrophages and phenotypically altered vascular
smooth muscle cells (VSMC) secrete a plethora of protein-
ases, including matrix metalloproteinases (MMPs)11,12. It
has been proposed that these enzymes contribute to
plaque rupture; thus, inhibition of MMPs within the athero-
sclerotic plaque may prevent disruption and its clinical
sequelae.
Lee et al.5 show that a procyanidin-rich cocoa fraction
(CPF) and procyanidin B2 exerted a strong inhibitory effect
on the thrombin-induced expression and activation of the
latent zymogen form of MMP-2, pro-MMP-2, as well as
thrombin-induced migration and invasion of VSMC by
directly inhibiting activity of a membrane type of MMP,
MT1-MMP, via the kinase MEK1. This effect was even
greater than that achieved with red wine polyphenols,
known to afford beneficial changes in pathways related to
cardiovascular health.2 Thrombin is a multifunctional
serine protease generated at the site of vascular injury
that transforms fibrinogen to fibrin, activates platelets and
MMPs, and elicits multiple effects on endothelial cells and
VSMC including proinflammatory activity12; in fact, thrombin
is a potent inducer of MMP-2 in both cell types. Among
MMPs, MT1-MMP was the first shown to be membrane
anchored. It can degrade a variety of ECM components,
including fibrillar collagen 1, and is particularly suited for
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pericellular proteolysis; therefore, it has been shown to be
involved in cell migration and participates in distinct pro-
cesses relevant to the inflammatory context. In particular,
it is important for chemokine and nitric oxide-induced
angiogenesis and relevant for human monocyte endothelial
transmigration.13 It is interesting to note that constitutive
activation of MEK1 results in induction of angiogenesis and
atherosclerosis, whereas, as reported by Lee et al., 5 both
CPF and procyanidin B2 inhibited the expression of
pro-MMP-2 by directly inhibiting MEK1, likely providing
atherosclerotic protection.
Numerous studies have tried to dissect the roles of MMPs
in atherosclerotic plaque development and instability with
the aid of a broad spectrum of MMP inhibitors. However,
results have been contradictory. For instance, doxycycline
treatment reduces the activity and/or expression of MMP-9
and MMP-1; however, in preliminary studies, no effect on
morphologic characteristics or clinical end-points was
observed in patients with atherothrombotic syndromes.14
It is becoming evident that MMPs can play distinct roles in
different cell types and, therefore, to dissect MMP function-
ality in distinct cell types may help to approach cell-type
specific inhibition of MMPs as a potential therapy for
atherosclerosis.15
There are still questions to be resolved. Does cocoa intake
achieve similar effects on MMP activation and cellular
migration in vivo? If so, what is the amount of cocoa
required to obtain anti-atherosclerotic effects and will
these be maintained over time? In conclusion, the authors
found favourable changes in cellular migration and
expression of MMPs in cocoa- and procyanidin-treated
VSMC. Provided their findings can be confirmed in vivo
they may partly explain the cardiovascular-protective role
of cocoa and other procyanidin derivatives. If cocoa inges-
tion indeed reduces coronary events, this issue will
become important as future studies are designed. It could
be inferred that adding modest amounts of dark chocolate,
which is derived from cocoa, to the diet can help to improve
cardiovascular health.
Conflict of interest: none declared.
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